Compare FMC Corp (FMC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? FMC Corp trades at $8.05 (market cap $1.29B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 3.8× FMC Corp's market cap, and FMC Corp pays a 3.85% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FMC | TVTX | |
|---|---|---|
Market Cap | $1.29B | $4.88B |
Volume | 3,528,603 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $67.52 |
52-Week Low | $8.09 | $26.79 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | $5.10B | $5.01B |
Dividend Yield | 3.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.09, down 2.76% on the day, with a bearish technical signal and weak fundamentals including a net income margin of -84.83% and negative ROE of -91.47% for 2025. Recent earnings show mixed results with Q2 2026 beating estimates, but revenue has declined from $5.8B in 2022 to $3.47B in 2025. Positive developments include a regulatory filing for rimisoxafen in Brazil and a minority equity investment by Tessenderlo Group, yet cash flow from operations remains negative.
The outlook is cautious; while analyst consensus is a buy with a $14.20 price target, high debt and cyclical industry headwinds pose significant risks. Aggressive deleveraging efforts may improve financial stability, but persistent revenue declines and negative profitability underscore substantial challenges for near-term recovery.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
